化学信息：
| 化学名 | 5-cyclopropyl-2-(4-fluorophenyl)-6-[2-hydroxyethyl(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide |
|
| 简称 | Nesbuvir | |
| 别名 |
HCV 796, HCV-796, HCV796 |
|
| 中文名 | N/A | |
| 化学式 | C22H23FN2O5S | |
| 分子量 | 446.49 | |
| CAS号 | 691852-58-1 | |
| 纯度 | 98% | |
| 溶剂/溶解度 |
Water<1mg/ml; DMSO5mg/ml; Ethanol<1mg/ml |
|
| 溶液配制 | 5mg加入1.12ml DMSO，或者每4.46mg加入1ml DMSO，配制成10mM溶液。SC3323-10mM用DMSO配制。 |
生物信息：
| 产品描述 | HCV-796 is a selectively inhibitor of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. | ||||
| 信号通路 | Anti-infection | ||||
| 靶点 | HCV | － | － | － | － |
| IC50 | 9nM | － | － | － | － |
| 体外研究 | Nesbuvir, a novel selective nonstructural protein 5B (NS5B) polymerase inhibitor, act as candidate for HCV treatment. HCV-796 reduced HCV RNA levels by 3 to 4 log(10) HCV copies/mug total RNA (the concentration of the compound that inhibited 50% of the HCV RNA level was 9nM). Cells bearing replicon variants with reduced susceptibility to HCV-796 were generated in the presence of HCV-796, followed by G418 selection. HCV-796 was reduced across different isolates. This reduction in inhibitory activity for non-nucleoside inhibitors (NNIs) was, in most cases, correlated with the existence of known NNI resistance mutations in the NS5B polymerase population of the clinical isolates, as detected by population sequencing. | ||||
| 体内研究 | N/A | ||||
| 临床实验 | N/A | ||||
| 特征 | N/A | ||||
相关实验数据(此数据来自于公开文献，碧云天并不保证其有效性)：
| 酶活性检测实验 | |
| 方法 | N/A |
| 细胞实验 | |
| 细胞系 | N/A |
| 浓度 | N/A |
| 处理时间 | N/A |
| 方法 | N/A |
| 动物实验 | |
| 动物模型 | N/A |
| 配制 | N/A |
| 剂量 | N/A |
| 给药方式 | N/A |
| 产品编号 | 产品名称 | 包装 |
| SC3323-10mM | Nesbuvir (HCV抑制剂) | 10mM×0.2ml |
| SC3323-5mg | Nesbuvir (HCV抑制剂) | 5mg |
| SC3323-25mg | Nesbuvir (HCV抑制剂) | 25mg |
| — | 说明书 | 1份 |
保存条件：
-20℃保存，至少一年有效。5mg和25mg包装也可室温保存，至少6个月有效。如果溶于非DMSO溶剂，建议分装后-80℃保存，预计6个月内有效。
